Singing training versus usual care after lung cancer surgery (6–18 months post-operation)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults who had curative surgery for stage I non-small cell lung cancer 6–18 months earlier and who report persistent symptoms are randomized to either a structured Singing for Lung Health (SLH) program or usual care. The SLH intervention is delivered twice weekly via online sessions and combines vocal exercises with breathing and physical components tailored to lung patients. Outcomes include symptom burden (using EORTC measures), physical function, breathlessness, and health-related quality of life measured before and after the intervention. The control group receives the standard post-surgical follow-up and rehabilitation offers available locally.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients who display persistent symptoms 6-18 months (+/- one month) after surgical resection of localised lung cancer with video-assisted thoracoscopy (VATS) will be invited to participate in the study.

Inclusion criteria for the study include:

1. Persistent symptoms, i.e., an EORTC-QLQ-C30 symptom domain score (in any item) of ≥2 (="clinically relevant symptom or problem that should have healthcare professional attention"),
2. Surgery for stage I lung cancer 6-18 months (+/- one month) earlier,
3. Motivated for participating in the project (and acceptance of randomisation procedure),
4. Access to a computer or a tablet with internet access,
5. Ability to speak and understand Danish,
6. Acceptance of the scheduled times of the singing intervention twice a week.

Exclusion Criteria:

Exclusion criteria include:

1. Unstable coronary diseases,
2. Severe cognitive disabilities (e.g., dementia),
3. Indication for adjuvant chemotherapy or other antineoplastic therapy,
4. Signs of lung cancer recurrence at regular follow-up CT scan.

No previous singing experience or musical competence is required. Participants will be informed that they are allowed to participate in additional offer of structured or unstructured offer physical exercise training and/or singing along with the project.

Where it's running

• August Krogh Section for Molecular and Human Physiology, Department of Nutrition, Exercise, and Sports, Faculty of Health and Medical Sciences, University of Copenhagen
  Copenhagen, Denmark Recruiting
• Department of Respiratory Medicine, Bispebjerg Hospital
  Copenhagen, Denmark Recruiting
• Department of Medicine Roskilde and Næstved, Zealand University Hospital
  Næstved, Denmark Recruiting
• Department of Respiratory Medicine, Odense University Hospital
  Odense, Denmark Recruiting
• Department of Respiratory Medicine, Lillebaelt Hospital
  Vejle, Denmark Recruiting

Study contacts

• Study coordinator: Mette Kaasgaard, PhD
• Email: mkaasgaard@health.sdu.dk
• Phone: 4528940238

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.